Zobrazeno 1 - 10 of 210 pro vyhledávání: '"Rackelmann, N."'
1
Akademický článek
SAR340835, a Novel Selective Na + /Ca 2+ Exchanger Inhibitor, Improves Cardiac Function and Restores Sympathovagal Balance in Heart Failure.
Autor: Pelat M; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Barbe F; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Daveu C; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Ly-Nguyen L; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Lartigue T; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Marque S; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Tavares G; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Ballet V; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Guillon JM; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Steinmeyer K; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Wirth K; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Gögelein H; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Arndt P; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Rackelmann N; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Weston J; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Bellevergue P; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., McCort G; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Trellu M; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Lucats L; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Beauverger P; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Pruniaux-Harnist MP; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Janiak P; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.)., Chézalviel-Guilbert F; Cardiovascular and Metabolism TSU (M.P., F.B., C.D., T.L., S.M., G.T., L.L., Ph.B., M.-P.P.-H., P.J., F.C.-G.) and Integrated Drug Discovery (Pa.B.), Sanofi R&D, Chilly Mazarin, France; Preclinical Safety, Sanofi R&D, Alfortville, France (L.L.-N., V.B., J.-M.G., M.T.); Sanofi R&D, Industriepark Höchst, Frankfurt, Germany (K.S., K.W., H.G., P.A., N.R., J.W.); and Integrated Drug Discovery, Sanofi R&D, Vitry sur Seine, France (G.M.) frederique.guilbert@sanofi.com.
Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2021 May; Vol. 377 (2), pp. 293-304. Date of Electronic Publication: 2021 Feb 18.
Zobrazit plný text záznamu
2
Akademický článek
Photoredox-Mediated Hydrogen Isotope Exchange Reactions of Amino-Acids, Peptides, and Peptide-Derived Drugs.
Autor: Legros F; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Fernandez-Rodriguez P; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Mishra A; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Weck R; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Bauer A; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Sandvoss M; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Ruf S; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Méndez M; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Mora-Radó H; TIDES, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Rackelmann N; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Pöverlein C; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany., Derdau V; Integrated Drug Discovery, Sanofi-Aventis (Deutschland) GmbH, Industriepark Höchst, 65926, Frankfurt, Germany.
Publikováno v: Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2020 Oct 06; Vol. 26 (56), pp. 12738-12742. Date of Electronic Publication: 2020 Sep 16.
Zobrazit plný text záznamu
3
Akademický článek
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Autor: Méndez M; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Matter H; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Defossa E; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Kurz M; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Lebreton S; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Li Z; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Lohmann M; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Löhn M; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Mors H; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Podeschwa M; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Rackelmann N; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Riedel J; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Safar P; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Thorpe DS; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Schäfer M; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Weitz D; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany., Breitschopf K; Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt, Germany.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2020 Mar 12; Vol. 63 (5), pp. 2292-2307. Date of Electronic Publication: 2019 Oct 23.
Zobrazit plný text záznamu
4
Akademický článek
From Facile One-Pot Synthesis of Semi-Degradable Amphiphilic Miktoarm Polymers to Unique Degradation Properties.
Autor: Kupczak, Maria1,2 (AUTHOR) maria.kupczak@impib.lukasiewicz.gov.pl, Mielańczyk, Anna1 (AUTHOR) anna.mielanczyk@polsl.pl, Fronczyk, Tomasz1 (AUTHOR) patryk.drejka@polsl.pl, Drejka, Patryk1 (AUTHOR) przemyslaw.ledwon@polsl.pl, Ledwon, Przemyslaw1 (AUTHOR) dorota.neugebauer@polsl.pl, Neugebauer, Dorota1 (AUTHOR)
Publikováno v: Materials (1996-1944). Jun2024, Vol. 17 Issue 11, p2684. 15p.
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the Na + /H + Exchanger Type 3 (NHE3).
Autor: Rackelmann N; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Matter H; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Englert H; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Follmann M; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Maier T; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Weston J; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Arndt P; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Heyse W; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Mertsch K; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Wirth K; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany., Bialy L; Sanofi-Aventis Deutschland GmbH, R&D , D-65926, Frankfurt am Main, Germany.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2016 Oct 13; Vol. 59 (19), pp. 8812-8829. Date of Electronic Publication: 2016 Sep 22.
Zobrazit plný text záznamu
9
Akademický článek
Recent Advances in Pyrimidine-Based Drugs.
Autor: Nammalwar, Baskar1 (AUTHOR) nbaskarphd@gmail.com, Bunce, Richard A.2 (AUTHOR) rab@okstate.edu
Publikováno v: Pharmaceuticals (14248247). Jan2024, Vol. 17 Issue 1, p104. 50p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje